Insmed Incorporated
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
INSM Key Statistics
Stock Snapshot
The current Insmed Incorporated(INSM) stock price is $147.10, with a market capitalization of 31.02B. The stock trades at a price-to-earnings (P/E) ratio of -21.24.
On 2026-03-23, Insmed Incorporated(INSM) stock traded between a low of $137.99 and a high of $152.00. Shares are currently priced at $147.10, which is +6.6% above the low and -3.2% below the high.
The Insmed Incorporated(INSM)'s current trading volume is 4.08M, compared to an average daily volume of 2.05M.
In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.
In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.
INSM News
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Insmed, with a price target of $205.00. Claim 30% Off TipRanks Premi...
Truist analyst Danielle Brill notes Insmed (INSM) announced that the Phase 3 ENCORE trial of Arikayce in newly diagnosed MAC lung disease was successful. The fi...
In early trading on Monday, shares of Insmed topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.4%. Year to date, Ins...
Analyst ratings
95%
of 21 ratingsMore INSM News
An announcement from Insmed ( (INSM) ) is now available. On March 23, 2026, Insmed reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE...
Insmed (INSM) announced positive topline results from the Phase 3b ENCORE study. This study evaluated ARIKAYCE plus multidrug therapy once-daily versus placebo...
Wells Fargo lowered the firm’s price target on Insmed to $175 from $208 and keeps an Overweight rating on the shares. The firm believes the pulmonary hypertensi...
In recent weeks, Insmed has attracted fresh attention as Jefferies initiated coverage with a positive view, while Artisan Partners highlighted the company’s rol...
Insmed (NasdaqGS:INSM) has launched Brinsupri, also known as brensocatib, for non cystic fibrosis bronchiectasis. Brinsupri is the first approved therapy for t...
Wondering whether Insmed at around US$144.60 a share looks expensive or still has room to run? This breakdown will help you connect the recent share price with...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.